KTA
TEVA icon

Keeley-Teton Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Keeley-Teton Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,603
Closed -$552K – 283
2017
Q2 		$552K Hold
16,603
– – 0.03% 233
2017
Q1 		$533K Buy
+16,603
New +$567K 0.02% 231

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Keeley-Teton Advisors's TEVA Position: Q3 2017 in Review

Keeley-Teton Advisors sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 16,603 shares — an estimated $552K sold.

Keeley-Teton Advisors first reported a position in TEVA in Q1 2017 and held it in 2 quarters. The position peaked at $552K in Q2 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Keeley-Teton Advisors reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Keeley-Teton Advisors sold 16,603 Teva Pharmaceuticals shares in Q3 2017, an estimated $552K.
  • Keeley-Teton Advisors first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Keeley-Teton Advisors's Teva Pharmaceuticals position peaked at $552K in Q2 2017.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Keeley-Teton Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.